Find Reports

Select Report Type

Reimbursement Review

Displaying 501 - 525 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
ertugliflozin	Steglatro	ertugliflozin	SR0565 Steglatro - CDEC Final Recommendation January 25, 2019 for posting.pdf sr0565-steglatro-clinical-report.pdf sr0565-steglatro-pharmacoeconomic-report.pdf sr0565-steglatro-patient-input.pdf	Diabetes mellitus, Type 2	Do not reimburse	Complete	Apr 30, 2018	Jan 23, 2019	SR0565-000
ertugliflozin and metformin	Segluromet	ertugliflozin and metformin hydrochloride	SR0566 Segluromet - CDEC Final Recommendation January 25, 2019 for posting.pdf sr0566-segluromet-combined-report.pdf	Diabetes mellitus, Type 2	Do not reimburse	Complete	Apr 30, 2018	Jan 23, 2019	SR0566-000
Lenvima for Renal Cell Carcino...	Lenvima	Lenvatinib	pcodr_profund_lenvatinib_lenvima_rcc_10140.pdf 10140LenvatinibRCC_FnRec_approvedbyChair_Post_04Jan2019_final.pdf 10140LenvatinibRCC_fnCGR_REDACT_Post_04Jan2019_final.pdf 10140LenvatinibRCC_fnEGR_NOREDACT-ABBREV_Post_04Jan2019_final.pdf pcodr_lenvatinib_lenvima_rcc_in_rec.pdf 10140_Lenvatinib_RCC_PAGFeedbackSummary_FINAL_Post_04Jan2019_final.pdf 10140LenvatinibRCC_SubmitterFeedback_2018-11-29_updated_Post_04Jan2019_final.pdf 10140LenvatinibRCC_PatientGroupFeedback_KCC_2018-11-15_Post_04Jan2019_final.pdf 10140LenvatinibRCC_ClinicianFeedback_Combined_Post_04Jan2019_final_Redacted.pdf 10140LenvatinibRCC_COI_KCC_2018-06-22_Post_04Jan2019_draft_Redacted.pdf 10140LenvatinibRCC_Combined_Clinician COIs_Post_04Jan2019_final.pdf	Renal Cell Carcinoma (RCC)	Do not reimburse	Complete	Jun 8, 2018	Jan 4, 2019	PC0140 -000
Tagrisso for Non-Small Cell Lu...	Tagrisso	Osimertinib	pcodr_provfund_osimertinib_tagrisso_nsclc_1ln.pdf 10137OsimertinibNSCLC_FnRec_2019-01-02_ChairApproved_Post_04Jan2019_final.pdf 10137OsimertinibNSCLC_fnCGR_NOREDACT_Post_04Jan2019_final.pdf 10137OsimertinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_04Jan2019_final.pdf pcodr_osimertinib_tagrisso_nsclc_1stln_in_rec.pdf 10137_Osimertinib_NSCLC_1L_PAGFeedbackSummary_FINAL_Post_04Jan2019_final.pdf 10137OsimertinibNSCLC(firstline)_SubmitterFeedback_2018-11-15_Post_04Jan2019_final.pdf 10137OsimertinibNSCLC(firstline)_PatientGroupFeedback_LCC_2018-11-15_Post_04Jan2019_final.pdf 10137OsimertinibNSCLC(firstline)_ClinicianFeedback_Combined_Post_04Jan2019_Redacted_final_Redacted.pdf 10137OsimertinibNSCLC_COI_LCC_2018-05-31_Post_04Jan2019_final_Redacted.pdf 10137OsimertinibNSCLC_COI Combined_Post_04Jan2019_final.pdf	Non-Small Cell Lung Cancer (NSCLC) (first line)	Reimburse with clinical criteria and/or conditions	Complete	May 16, 2018	Jan 4, 2019	PC0137-000
sucroferric oxyhydroxide	Velphoro	sucroferric oxyhydroxide	SR0571 Velphoro - CDEC Final Recommendation January 4, 2019 for posting.pdf sr0571-velphoro-clinical-report.pdf sr0571-velphoro-pharmacoeconomic-report.pdf sr0571-velphoro-patient-input.pdf	Hyperphosphatemia, end-stage renal disease	Reimburse with clinical criteria and/or conditions	Complete	Jun 12, 2018	Jan 2, 2019	SR0571-000
lixisenatide + insulin glargin...	Soliqua	lixisenatide + insulin glargine	SR0564 Soliqua - CDEC Final Recommendation January 3, 2019 for posting.pdf sr0564-soliqua-clinical-report.pdf sr0564-soliqua-pharmacoeconomic-report.pdf sr0564-soliqua-patient-input.pdf	Diabetes mellitus, Type 2	Reimburse with clinical criteria and/or conditions	Complete	May 18, 2018	Dec 24, 2018	SR0564-000
fluticasone propionate	Aermony RespiClick	fluticasone propionate	SR0539 Aermony RespiClick - CDEC Final Recommendation for posting December 21, 2018.pdf sr0539-aermony-respiclick-clinical-report.pdf sr0539-aermony-respiclick-pe-report.pdf sr0539-aermony-respiclick-PI-submissions.pdf	Asthma	Reimburse with clinical criteria and/or conditions	Complete	Oct 4, 2017	Dec 19, 2018	SR0539-000
fluticasone propionate / salme...	Arbesda RespiClick	fluticasone propionate / salmeterol xinafoate	SR0540 Arbesda RespiClick - CDEC Final Recommendation for Posting December 21, 2018.pdf sr0540-arbesda-respiclick_combined-report.pdf sr0540_arbesda-respiclick_PI_submissions.pdf	Asthma	Reimburse with clinical criteria and/or conditions	Complete	Oct 4, 2017	Dec 19, 2018	SR0540-000
Opdivo for Hepatocellular Carc...	Opdivo	Nivolumab	pcodr_provfund_nivolumab_opdivo_hcc.pdf pcodr_nivolumab_opdivo_hcc_fn_rec.pdf pcodr_nivolumab_opdivo_hcc_fn_cgr.pdf pcodr_nivolumab_opdivo_hcc_fn_egr.pdf pcodr_nivolumab_opdivo_hcc_in_rec.pdf pcodr_nivolumab_opdivo_hcc_pagfdk.pdf pcodr_nivolumab_opdivo_hcc_bmsc.pdf pcodr_nivolumab_opdivo_hcc_clnfdk.pdf pcodr_nivolumab_opdivo_hcc_coi_pt.pdf pcodr_nivolumab_opdivo_hcc_coi_cln.pdf	Metastatic Hepatocellular Carcinoma (HCC)	Do not reimburse	Complete	May 8, 2018	Nov 29, 2018	PC0134-000
Perjeta-Herceptin Combo Pack f...	Perjeta-Herceptin Combo Pack	Pertuzumab-Trastuzumab Combo Pack	pcodr_provfund_10127perjeta-herceptin-combo_ebc.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_rec.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_cgr.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_egr.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_in_rec.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_pagfdk.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_hlr.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_ptfdk.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_clnfdk.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_coi_pt.pdf pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_coi_cln.pdf	Early Breast Cancer	Do not reimburse	Complete	Apr 9, 2018	Nov 29, 2018	PC0127-000
Rivaroxaban	Xarelto	Rivaroxaban	SR0569 Xarelto - Confidential Final CDEC Recommendation (redacted)_for posting.pdf SR0569_Xarelto_CL_Report.pdf SR0569_Xarelto_PE_Report.pdf	Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.	Reimburse with clinical criteria and/or conditions	Complete	May 24, 2018	Nov 20, 2018	SR0569-000
Opdivo in combo with Yervoy fo...	Opdivo in combination with Yervoy	Nivolumab in combination with Ipilimumab	pcodr_profund_10132opdivo-yervoy_rcc.pdf pcodr_opdivo_yervoy_rcc_fn_rec.pdf pcodr_opdivo_yervoy_rcc_fn_cgr.pdf pcodr_opdivo_yervoy_rcc_fn_egr.pdf pcodr_opdivo_yervoy_rcc_in_rec.pdf pcodr_opdivo_yervoy_rcc_pagfdk.pdf pcodr_opdivo_yervoy_rcc_fdk_bms.pdf pcodr_opdivo_yervoy_rcc_clnfdk.pdf pcodr_opdivo_yervoy_rcc_coi_pt.pdf pcodr_opdivo_yervoy_rcc_coi_cln.pdf	Advanced or Metastatic Renal Cell Carcinoma (RCC).	Reimburse with clinical criteria and/or conditions	Complete	Apr 26, 2018	Nov 1, 2018	PC0132-000
Gazyva for Follicular Lymphom...	Gazyva	Obinutuzumab	pcodr_provfund_10126obinutuzumab_gazyva_fl_preun.pdf pcodr_obinutuzumab_gazyva_fl_preun_fn_rec.pdf pcodr_obinutuzumab_gazyva_fl_preun_fn_cgr.pdf pcodr_obinutuzumab_gazyva_fl_preun_fn_egr.pdf pcodr_obinutuzumab_gazyva_fl_preun_in_rec.pdf pcodr_obinutuzumab_gazyva_fl_preun_pagfdk.pdf pcodr_obinutuzumab_gazyva_fl_preun_fdk_hlr.pdf pcodr_obinutuzumab_gazyva_fl_preun_clnfdk.pdf pcodr_obinutuzumab_gazyva_fl_preun_coi_pt.pdf pcodr_obinutuzumab_gazyva_fl_preun_coi_cln.pdf	Follicular Lymphoma (previously untreated)	Do not reimburse	Complete	Mar 15, 2018	Nov 1, 2018	PC0126-000
Erleada for Castrate Resistant...	Erleada	Apalutamide	pcodr_provfund_apalutamide_erleada_nm-cprc.pdf pcodr_apalutamide_erleada_crpc_fn_rec.pdf pcodr_apalutamide_erleada_crpc_fn_cgr.pdf pcodr_apalutamide_erleada_crpc_fn_egr.pdf pcodr_apalutamide_erleada_crpc_in_rec.pdf pcodr_apalutamide_erleada_crpc_pagfdk.pdf pcodr_apalutamide_erleada_crpc_fdk_janssen.pdf pcodr_apalutamide_erleada_crpc_ptfdk.pdf pcodr_apalutamide_erleada_crpc_clnfdk.pdf pcodr_apalutamide_erleada_crpc_coi_pt.pdf pcodr_apalutamide_erleada_crpc_coi_cln.pdf	non-metastatic castrate resistant prostate cancer (nm-CRPC)	Reimburse with clinical criteria and/or conditions	Complete	Apr 16, 2018	Nov 1, 2018	PC0133-000
bictegravir/emtricitabine/teno...	Biktarvy	bictegravir/emtricitabine/tenofovir alafenamide	SR0567 Biktarvy - CDEC Final Recommendation October 29, 2018.pdf SR0567_Biktarvy_CL_Report.pdf SR0567_Biktarvy_PE_Report.pdf SR0567_Biktarvy_PI_Submissions.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Apr 30, 2018	Oct 25, 2018	SR0567-000
cladribine	Mavenclad	cladribine	TS0004-Cladribine-Natalizumab_Updated_Recommendations.pdf SR0546-Mavenclad_Oct-26-18.pdf SR0546_Mavenclad_CL_Report.pdf SR0546_Mavenclad_PE_Report.pdf SR0546_Mavenclad_PI_Submissions.pdf	Multiple Sclerosis, relapsing-remitting	Reimburse with clinical criteria and/or conditions	Complete	Dec 1, 2017	Oct 24, 2018	SR0546-000
ozenoxacin	Ozanex	ozenoxacin	SR0553_Ozanex_Oct-26-18.pdf SR0553_Ozanex_CL_Report.pdf SR0553_Ozanex_PE_Report.pdf SR0553_Ozanex_PI_Submissions.pdf	Impetigo	Do not reimburse	Complete	Jan 25, 2018	Oct 24, 2018	SR0553-000
dexamethasone	Ozurdex	dexamethasone	SR0535_Ozurdex_Oct-26-18.pdf SR0535_Ozurdex _CL_Report.pdf SR0535_Ozurdex_PE_Report .pdf SR0535_Ozurdex_PI_Submissions.pdf	Diabetic macular edema	Do not reimburse	Complete	Sep 26, 2017	Oct 24, 2018	SR0535-000
Tapentadol Hydrochloride	Nucynta	tapentadol hydrochloride	SR0563_Nucynta - CDEC Final Recommendation October 25, 2018.pdf SR0563_Nucynta_CL_Report.pdf SR0563_Nucynta_PE_Report.pdf SR0563_Nucynta_PI_Submissions.pdf	pain, severe	Do not reimburse	Complete	Apr 17, 2018	Oct 23, 2018	SR0563-000
sebelipase alfa	Kanuma	sebelipase alfa	SR0544 Kanuma - CDEC Final Recommendation September 28, 2018.pdf SR0544_Kanuma_CL_Report.pdf SR0544_Kanuma_PE_Report.pdf SR0544_Kanuma_PI_Submissions.pdf si0003-kanuma-cadth-drug-implementation-advice.pdf	Lysosomal acid lipase deficiency	Reimburse with clinical criteria and/or conditions	Complete	Nov 2, 2017	Sep 26, 2018	SR0544-000
lumacaftor/ivacaftor	Orkambi	lumacaftor/ivacaftor	SR0559 Orkambi - CDEC Final Recommendation October 4, 2018.pdf SR0559_Orkambi_CL_Report.pdf SR0559_Orkambi_PE_Report.pdf SR0559_Orkambi_PI_Submissions.pdf	Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older	Do not reimburse	Complete	Feb 22, 2018	Sep 26, 2018	SR0559-000
eluxadoline	Viberzi	eluxadoline	SR0560_cdr_complete_Viberzi_Aug_29_18.pdf SR0560_Viberzi_CL_Report.pdf SR0560_Viberzi_PE_Report.pdf SR0560_Viberzi_PI_Submissions.pdf	Irritable bowel syndrome with diarrhea	Do not reimburse	Complete	Feb 23, 2018	Aug 24, 2018	SR0560-000
abobotulinumtoxinA	Dysport Therapeutic	abobotulinumtoxinA	SR0556_Dysport_Therapeutic_Aug_23_18.pdf SR0556_Dysport_Therapeutic_CL_Report.pdf SR0556_Dysport_Therapeutic_PE_Report.pdf SR0556_Dysport_PI_Submissions.pdf	lower limb spasticity	Reimburse with clinical criteria and/or conditions	Complete	Feb 7, 2018	Aug 23, 2018	SR0556-000
fluticasone furoate/umeclidini...	Trelegy Ellipta	fluticasone furoate umeclidinium vilanterol	SR0562_cdr_complete_Trelegy_Ellipta_Aug_27_18.pdf SR0562_TrelegyEllipta_CL_Report.pdf SR0562_TrelegyEllipta_PE_Report.pdf SR0562_TrelegyEllipta_PI_Submissions.pdf	Chronic obstructive pulmonary disease (COPD)	Reimburse with clinical criteria and/or conditions	Complete	Mar 1, 2018	Aug 23, 2018	SR0562-000
nitisinone	Nitisinone	nitisinone	SR0554_Nitisinone_Aug_23_18.pdf SR0554_Nitisinone_CL_Report.pdf SR0554_Nitisinone_PE_Report.pdf SR0554_Nitisinone_PI_Submissions.pdf	Hereditary tyrosinemia type 1	Reimburse with clinical criteria and/or conditions	Complete	Jan 25, 2018	Aug 23, 2018	SR0554-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 501 - 525 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Pleuroscopy for the Diagnosis of Cancer in Patients with Pleural Effusion: A Review of the Diagnostic Accuracy, Safety, Cost-Effectiveness and Guidelines	RC1260 Pleuroscopy Final.pdf	Apr 27, 2020	Summary with Critical Appraisal	Completed	RC1260-000
Psychotherapy for the Treatment of Acute Musculoskeletal Pain: A Review of Clinical Effectiveness and Guidelines	RC1262 Psychotherapy Acute Pain Final.pdf	Apr 27, 2020	Summary with Critical Appraisal	Completed	RC1262-000
Non-invasive Nerve Stimulation Modalities for Migraine Pain: A Review of Clinical Effectiveness and Cost-effectiveness	RC1265 NINS for Migraine Final.pdf	Apr 27, 2020	Summary with Critical Appraisal	Completed	RC1265-000
Epinephrine Auto-Injectors for Anaphylaxis: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1269 Epinephrine Auto-Injector Final.pdf	Apr 27, 2020	Summary with Critical Appraisal	Completed	RC1269-000
Customized or Prefabricated Shoe Inserts for Chronic, Non-Cancer Pain: A Review of Clinical Effectiveness	RC1259 Orthotics Pain Final.pdf	Apr 20, 2020	Summary with Critical Appraisal	Completed	RC1259-000
Harmonization of Public Coverage Policies for Biologic Drugs in the Treatment of Rheumatoid Arthritis	Optimal Use 360 Report Utilization Review Budget Impact Analysis	Apr 17, 2020		Complete	HD0001-000
Skin Preparation for Injections: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines	RC1218 Skin Prep Injection Final corrected.pdf	Apr 16, 2020	Summary with Critical Appraisal	Completed	RC1218-000
Exercise for the Treatment of Ankle Sprain: A Review of Clinical Effectiveness and Guidelines	RC1261 - Exercise ankle sprain Final.pdf	Apr 13, 2020	Summary with Critical Appraisal	Completed	RC1261-000
Bacille Calmette-Guérin Vaccination: A Review of Clinical Effectiveness and Guidelines	RC1264 BCG Vaccination Final.pdf	Apr 6, 2020	Summary with Critical Appraisal	Completed	RC1264-000
Masks for Prevention of Influenza Transmission in Acute and Long-Term Care Settings: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines	RC1255 Influenza Masks Final.pdf	Mar 31, 2020	Summary with Critical Appraisal	Completed	RC1255-000
Intravitreal Dexamethasone Implants for Non-infectious Uveitis: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines	RC1257-000 Ozurdex Uveitis Final.pdf	Mar 31, 2020	Summary with Critical Appraisal	Completed	RC1257-000
Body Weight Modification Interventions for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness	RC1258 Weight change pain Final.pdf	Mar 31, 2020	Summary with Critical Appraisal	Completed	RC1258-000
Assessment of Dehydration and Oral Rehydration Therapy for Pediatric Patients with Dehydration: A Review of Clinical Effectiveness, Clinical Utility, and Guidelines	RC1240 ORT diagnosis treatment Final.pdf	Mar 23, 2020	Summary with Critical Appraisal	Completed	RC1240-000
Propranolol for Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness	RC1254 Propranolol PTSD Final.pdf	Mar 23, 2020	Summary with Critical Appraisal	Completed	RC1254-000
Serial X-Ray Radiography for the Diagnosis of Osteomyelitis: A Review of Diagnostic Accuracy, Clinical Utility, Cost-Effectiveness, and Guidelines	RC1256 Serial Radiography Osteomyelitis Final.pdf	Mar 23, 2020	Summary with Critical Appraisal	Completed	RC1256-000
Experiences with and Expectations of Robotic Surgical Systems: A Rapid Qualitative Review	RC1251 RSS for Gyno Uro Surgery Final.pdf	Mar 19, 2020	Summary with Critical Appraisal	Completed	RC1251-000
The Use of Real-World Evidence for Medical Device Assessment ─ An Environmental Scan		Mar 19, 2020			ES0344-000
The Use of Real-World Evidence for Medical Device Assessment: An Environmental Scan		Mar 19, 2020			ES0344-000
Identification of Tuberculosis: A Review of the Guidelines	RC1236 TB identification Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1236-000
Drug-Resistant Tuberculosis: A Review of the Guidelines	RC1239 DR-TB guidelines Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1239-000
Treatment of Tuberculosis: A Review of Guidelines	RC1237 TB treatment guidelines Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1237-000
Tuberculosis in People with Compromised Immunity: A Review of Guidelines	RC1238 TB immunocompromised Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1238-000
Prevention of Tuberculosis: A Review of Guidelines	RC1223 TB prevention guidelines Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1223-000
Oral Rehydration Solutions versus Drink of Choice in Children with Dehydration: A Review of Clinical Effectiveness	RC1241 ORS Final.pdf	Mar 9, 2020	Summary with Critical Appraisal	Completed	RC1241-000
Local Anesthetic for Urinary Catheter Insertion: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1250 Urinary Catheter Anaesthetic Final.pdf	Mar 9, 2020	Summary with Critical Appraisal	Completed	RC1250-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 501 - 525 of 2138

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Clinical and Instrumental Swallowing Assessments for Dysphagia		Clinical and Instrumental Swallowing Assessments for Dysphagia	Feb 23, 2024	Health Technology Review	Rapid Review	Completed	RC1526-000
Renal cell carcinoma		Final Report	Feb 21, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0037-000
cabozantinib		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 15, 2024	Reimbursement Review		Complete	PC0312-000
elexacaftor/tezacaftor/ivacaftor and ivacaftor		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 9, 2024	Reimbursement Review		Complete	SR0776-000
mirikizumab		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 9, 2024	Reimbursement Review		Complete	SR0773-000
ibrutinib		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 9, 2024	Reimbursement Review		Complete	PC0317-000
Average Volume of MRI Exams Conducted per Hour Across Canada	Using data from the national Canadian Medical Imaging Inventory 2019 to 2020 survey, we calculated an average of MRI exams performed per hour across Canada	Average Volume of MRI Exams Conducted per Hour Across Canada	Jan 31, 2024	Health Technology Review	CMII Service	Completed	CM0008-000
Biologic Drugs for Severe Asthma		Final Report Summary Report	Jan 30, 2024	Health Technology Review	Technology Review	Completed	RE0047-000
Buprenorphine Formulations for Opioid Use Disorder		Buprenorphine Formulations for Opioid Use Disorder	Jan 30, 2024	Health Technology Review	Systematic Review	Completed	RE0051-000
nelarabine		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 26, 2024	Reimbursement Review		Complete	PC0307-000
CADTH Pharmaceutical Reviews Update — Issue 43			Jan 25, 2024	Reimbursement Review	Pharmaceutical Review Update
durvalumab and tremelimumab		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 25, 2024	Reimbursement Review		Complete	PC0308-000
The Safety of Niraparib in Ovarian Cancer	To give clinicians and policy-makers a better understanding of the niraparib’s risk profile, researchers conducted an observational study to look at how the safety and tolerability of niraparib in the real world compares with observations from seminal clinical trials.	Summary Report for Policy-Makers Summary Report for Clinicians Plain Language Summary Report Observational Study - The Safety of Niraparib in Ovarian Cancer Final Protocol	Jan 24, 2024	Health Technology Review	Observational Study	Active	OS0002-000
Unresectable Hepatocellular Carcinoma		Final Report	Jan 24, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0036-000
Chatbots in Health Care: Connecting Patients to Information		Chatbots in Health Care: Connecting Patients to Information	Jan 24, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH0122-000
Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update	We conducted a review of the clinical effectiveness, cost-effectiveness, and evidence-based guidelines on the use of ketamine in adults with TRD or PTSD, to help guide decisions on the use of ketamine for managing these conditions.	Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update	Jan 23, 2024	Health Technology Review	Rapid Review	Completed	RC1522-000
axicabtagene ciloleucel		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Jan 22, 2024	Reimbursement Review		Complete	PG0314-000
Endobronchial Valves for the Management of Severe Emphysema		Endobronchial Valves for the Management of Severe Emphysema	Jan 18, 2024	Health Technology Review	Rapid Review	Completed	RC1524-000
Ketorolac for Renal Colic		Ketorolac for Renal Colic	Jan 18, 2024	Health Technology Review	Rapid Review	Completed	RC1525-000
Immune checkpoint inhibitors for mutated non–small cell lung cancer			Jan 15, 2024	Health Technology Review	Observational Study	In Progress	OS0008-000
Artificial Intelligence– Enhanced Rapid Response Electroencephalography for the Identification of Nonconvulsive Seizure		Artificial Intelligence– Enhanced Rapid Response Electroencephalography for the Identification of Nonconvulsive Seizure	Jan 9, 2024	Horizon Scan	Health Technology Update	Completed	EN0054-000
Leucovorin Dosing for Gastrointestinal Cancer		Leucovorin Dosing for Gastrointestinal Cancer	Jan 9, 2024	Health Technology Review	Rapid Review	Completed	RC1518-000
Ketamine for Chronic Non-Cancer Pain: A 2023 Update		Ketamine for Chronic Non-Cancer Pain: A 2023 Update	Jan 9, 2024	Health Technology Review	Summary with Critical Appraisal	Completed	RC1521-000
Screening for Colorectal Cancer in Individuals Younger Than 50 Years		Screening for Colorectal Cancer in Individuals Younger Than 50 Years	Jan 8, 2024	Health Technology Review	Rapid Review with Expert Input	Completed	RD0069-000
Perspectives and Experiences Regarding the Creation of Arteriovenous Fistulas for Hemodialysis Access: A Rapid Qualitative Review		Perspectives and Experiences Regarding the Creation of Arteriovenous Fistulas for Hemodialysis Access: A Rapid Qualitative Review	Jan 8, 2024	Health Technology Review	Rapid Review	Completed	RC1519-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81